Nurix Therapeutics, Inc. NRIX AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss
AFS and Trading Securities - Unrealized Loss Position (>=12 Months) Accumulated Loss at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s afs and trading securities - unrealized loss position (>=12 months) accumulated loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) accumulated loss?
- Nurix Therapeutics, Inc. (NRIX) reported AFS and trading securities - unrealized loss position (>=12 months) accumulated loss of $0 in Q4 2025.
- How has Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) accumulated loss changed year-over-year?
- Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (>=12 months) accumulated loss decreased by 100.0% year-over-year, from $8K to $0.